Isoalantolactone

Isoalantolactone

1. Identity: Chemical and Botanical Characterization

1.1 Nomenclature and Chemical Classification

Isoalantolactone (ISA; CAS No. 470-17-7) is an eudesmane-type sesquiterpene lactone. The eudesmane skeleton is a bicyclic framework characteristic of a broad subclass within the sesquiterpene family. Sesquiterpene lactones as a class are characterized by a 15-carbon skeleton derived from three isoprene units and the presence of a lactone ring. Quantitative structure–activity relationship (QSAR) studies have indicated that the biological activities of sesquiterpene lactones, including cytotoxicity, are mediated chemically by moieties such as the α-methylene-γ-lactone group present in isoalantolactone. This reactive α-methylene-γ-lactone moiety enables the molecule to interact with nucleophilic targets such as thiol groups on proteins, a property central to many of its observed biological effects.

Isoalantolactone (ISA, CAS No. 470-17-7) is an eudesmane-type sesquiterpene lactone that exists in the leaves and roots of many plants. It is a structural isomer of alantolactone, differing from it in the orientation of the methylene-lactone group, with both compounds frequently co-occurring in their source plants.

1.2 Natural Sources and Botanical Origin

Isoalantolactone can be isolated from Inula helenium as well as many other herbal plants belonging to Asteraceae. Inula helenium L. (elecampane) is the most historically prominent and pharmaceutically documented source. Isoalantolactone is known to be a major sesquiterpene lactone found in the roots of the Inula species.

Sesquiterpene lactones are a stable class of terpenoids that have been isolated from a number of plant families, but the greatest number has been isolated from the Asteraceae (Compositae) family, with over 300 reported different structures. Beyond Inula helenium, isoalantolactone has been identified in other species within the same genus, including Inula racemosa and Inula japonica, as well as in Saussurea species. Isoalantolactone was isolated and identified as one of the major cytotoxic compounds in an Artemisia afra ethanol extract. Occurrence has also been documented in Inula sp. and Saussurea sp.

The natural sources of ISA include a range of plants. ISA is one of the active components from many Traditional Chinese Medicine (TCM) materials and formulas, including TuMuXiang (Radix inulae, dried roots of I. helenium and Inula racemosa Hook f.), Mongolian medicine prescriptions Roukou Wuwei pills, Liuwei Anxiao San, Tibetan medicine Zuozhu Daxi, and Ershi-wei Chenxiang pills.

1.3 Plant Description and Plant-Part Use

Radix Inulae is a commonly used traditional Chinese and Tibetan medicine. The root contains up to 44% of the carbohydrate inulin as well as mucilage. Sesquiterpenes isolated from the plant include a germacrane, an elemane, and the eudesmanes alantolactone, isoalantolactone, as well as several derivatives. Sterols include β-sitosterol and its glucoside, and stigmasterol. Isoalantolactone is concentrated predominantly in the root, which is the plant part most commonly employed medicinally. Inula helenium has been used as a traditional medicine in China for over 2,000 years and is an official plant recorded in the Chinese Pharmacopoeia and some European Pharmacopoeias.

1.4 Common Forms and Preparations

Isoalantolactone is encountered in several forms:

• Crude root preparations: Dried root (Radix inulae), employed as decoctions, teas, and hydroethanolic tinctures in both Western and Eastern traditional medicine.
• Standardized extracts: Ethanolic and hydroethanolic extracts of Inula helenium root, used as source material in pharmacological research. Traditional hydro-ethanolic extracts have been prepared from multi-origin elecampane roots.
• Isolated pure compound: Isoalantolactone is available as a purified reference standard for laboratory use, certified as a primary reference standard with certified absolute purity (considering chromatographic purity, water, residual solvents, and inorganic impurities).
• Semi-synthetic derivatives and conjugates: Amino adducts improve the solubility in water and pharmacokinetics, and retain the antitumor activity. A range of synthetic conjugates have been reported, including isoalantolactone-tryptamine conjugates, anthracycline antibiotics (daunorubicin and doxorubicin) conjugates, thiophenol conjugates, selenophenol conjugates, piperazine conjugates, halopyridine conjugates, and serotonin conjugates.

Quantitatively, under microwave-assisted extraction conditions using 1 g plant sample mixed with 15 mL of 80% ethanol solution and microwave radiation for 120 seconds at 50°C, the yield of isoalantolactone from I. helenium root was found to be 21.25 ± 1.37 mg/g.

2. Traditional and Historical Use

2.1 European and Western Traditions

Elecampane has been used since the days of ancient Greece and Rome and was included in the U.S. Pharmacopeia as a remedy for bronchial congestion. It was well cultivated in medieval herb and monastery gardens and was used in England before the Norman conquest. The primary vehicle for isoalantolactone exposure in these traditions was the root of Inula helenium, prepared as decoctions, tinctures, or syrups.

In Irish ethnomedical literature, Inula helenium L. (elecampane) is often indicated for respiratory and dermal ailments. Traditional Chinese and Indian Ayurvedic medicine used elecampane for bronchitis and asthma, as did ancient Greeks and Romans. In the 1800s, lozenges, candy, and cough drops were all produced from elecampane root.

Respiratory use was the central application. Historically, isoalantolactone-containing preparations were most commonly used to address respiratory ailments such as coughs, bronchitis, and asthma. The root was often brewed into teas or decoctions, believed to soothe the throat, loosen phlegm, and support overall lung health.

2.2 Traditional Chinese Medicine, Tibetan Medicine, and Mongolian Medicine

Radix Inulae is a commonly used traditional Chinese and Tibetan medicine, particularly for its gastric effects and antibacterial action. In TCM, the dried root drug TuMuXiang (Radix inulae), derived from I. helenium and I. racemosa, is a recognized medicinal substance. ISA is one of the active components from TCM formulas including TuMuXiang, Mongolian medicine prescriptions Roukou Wuwei pills, and Liuwei Anxiao San, Tibetan medicine Zuozhu Daxi and Ershi-wei Chenxiang pills.

2.3 Ayurvedic and Native American Traditions

The Ayurvedic tradition uses elecampane for respiratory complaints, rheumatism, and skin problems including bites and stings. Inula was a medicine-chest plant for Native Americans who used it for tuberculosis, general respiratory support (for humans and horses), as a gastrointestinal aid, an analgesic for chest pains, rheumatism, as a cathartic, a vulnerary, a diaphoretic, and for stroke.

2.4 Digestive Uses

Beyond respiratory remedies, isoalantolactone-containing preparations have played a role in digestive health, being used to stimulate appetite, relieve indigestion, and address intestinal worms. The anthelmintic (worm-expelling) property was particularly well documented across multiple traditions, including use in European folk medicine for intestinal parasites.

3. Key Constituents, Chemical Properties, and Mechanisms of Action

3.1 Structural Features and Reactivity

Sesquiterpene lactones are a large and structurally diverse class of natural products characterized by a 15-carbon skeleton derived from three isoprene units and the presence of a lactone ring. These compounds are secondary metabolites predominantly found in higher plants, particularly within the Asteraceae family. Their intricate chemical structures, often featuring an α-methylene-γ-lactone moiety, are crucial for their varied pharmacological properties, as this functional group can readily interact with biological nucleophiles.

In isoalantolactone specifically, the α-methylene-γ-lactone moiety confers the capacity for Michael-type addition reactions with thiol groups on cellular proteins. This mechanism underlies both its biological activities and its potential for skin sensitization (see Safety section). The eudesmane skeleton provides the bicyclic framework within which this reactive group is positioned.

3.2 Anticancer Mechanisms

ISA owns multiple pharmacological effects, including anticancer activity. The anticancer effects of ISA involve proliferation inhibition, ROS overproduction, apoptosis induction, and cell cycle arrest.

In prostate cancer cell lines (PC-3 and DU145), investigation found that isoalantolactone reduced the growth of prostate cancer cells through increased production of ROS, activation of the ER stress pathway, and inhibition of STAT3.

In breast cancer cells, two human breast cancer cell lines (MDA-MB-231 and MCF-7) and one normal breast cell line (MCF-10A) were applied. Data suggested that isoalantolactone decreased breast cancer cell viability in a dose-dependent manner but showed almost no toxicity to MCF-10A cells. The anticancer effects were related to the overexpression of reactive oxygen species. Isoalantolactone significantly induced breast cancer cell apoptosis by activating caspase cascade and cleaving poly (ADP-ribose) polymerase.

Increase of Bax/Bcl-2 ratio, depolarization of mitochondrial membrane potential, release of cytochrome c from mitochondria to cytoplasm, and cell cycle arrest at G2/M phase were associated with isoalantolactone's anticancer mechanism in breast cancer cells.

In colorectal cancer, investigation explored the anti-CRC effects and mechanism of action of isoalantolactone in vitro and in vivo. Results demonstrated that IATL inhibited proliferation by inducing G0/G1 phase cell cycle arrest, apoptosis, and autophagy in CRC cells. Repression of autophagy with autophagy inhibitors chloroquine and Bafilomycin A1 enhanced the anti-CRC effects of IATL, suggesting that IATL induces cytoprotective autophagy in CRC cells.

In glioblastoma, isoalantolactone inhibits IKKβ kinase activity to interrupt the NF-κB/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin.

Based on accumulating literature, alantolactone and isoalantolactone induce apoptosis by targeting multiple cellular signaling pathways that are frequently deregulated in cancers, suggesting that their simultaneous targeting by these compounds could result in efficacious and selective killing of cancer cells.

3.3 Anti-Inflammatory Mechanisms

Through inhibiting NF-κB signaling, ISA exerts its anti-inflammatory effects, which are also involved in the neuroprotection of ISA. The NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway is a master regulator of inflammatory gene expression, and its inhibition by ISA represents a well-documented mechanism documented across multiple experimental models.

Alantolactone and isoalantolactone have been reported for their wide spectrum of biological effects, including antifungal, anthelmintic activities, antimicrobial activities, anti-inflammatory activities, antitrypanosomal activities, and antiproliferative effects on several cancer cell lines, such as colon, melanoma, ovary, prostate, lung, and leukemia.

3.4 Neuroprotective Mechanisms

ISA can suppress the generation of ROS and superoxide anion induced by amyloid β peptide (Aβ25-35) in mouse cortical neurons while elevating intracellular GSH, attenuating the cytotoxicity of Aβ25-35 to neurons. In a mouse amnesia model induced by scopolamine, ISA can decrease the damages of the cornu ammonis regions of mouse hippocampus and alleviate cognitive impairment, as revealed by Y-maze, passive avoidance, and water maze tests; but in Nrf2−/− mice, this improvement was not seen. The neuroprotective mechanism may involve the inhibition of acetylcholinesterase, in addition to the activation of Nrf2 by ISA.

In vitro mechanistic studies showed that IAL regulated apoptosis-related proteins by activating the AKT/Nrf2 pathway, thereby suppressing the apoptosis of SN4741 cells induced by MPP+. IAL inhibited LPS-induced release of pro-inflammatory mediators in BV2 cells by activating the AKT/Nrf2/HO-1 pathway and inhibiting the NF-κB pathway.

4. Scientific Evidence by Area of Use

4.1 Anticancer Activity

Evidence Base

The entire body of evidence for ISA's anticancer effects as of 2024 is composed of cell-based (in vitro) studies and animal (in vivo) studies. No human clinical trials have been published. The existing evidence is therefore preliminary and cannot be extrapolated to therapeutic use in humans.

Cell Line Studies

Isoalantolactone, an active sesquiterpene naturally present in many vegetables and medicinal plants, was recently identified as selectively toxic to cancer cells. The pleiotropic anticancer effects of isoalantolactone have also been demonstrated in diverse malignancies including esophageal cancer, lung carcinoma, and breast cancer. Additional cancer types studied in vitro include pancreatic carcinoma (PANC-1), chronic myelogenous leukemia (K562), gastric cancer (SGC-7901), glioblastoma, colorectal cancer, endometrial cancer (HEC-1-B), prostate cancer (PC-3, DU145), and hepatocellular carcinoma (Hep3B).

Isoalantolactone was proved to induce apoptosis in pancreatic carcinoma PANC-1 cells, chronic myelogenous leukemia, K562/A02 cells, and SGC-7901 cells.

Isoalantolactone exerts anticancer effects on human HEC-1-B endometrial cancer cells via induction of ROS-mediated apoptosis and inhibition of MEK/ERK signalling pathway.

In Vivo (Animal) Studies

A nude mouse xenograft model was used to test the effects of isoalantolactone on prostate cancer cell growth in vivo. Isoalantolactone dose-dependently inhibited cancer cell growth and induced apoptosis in PC-3 and DU145 cells.

Evidence Strength

Weak to preliminary. Lots of further and deep explorations have to be undertaken before these pharmacological activities can be translated into therapeutic options for cancers, microbial infections, inflammatory diseases, and neurodegenerative disorders. All anticancer data is preclinical. No human studies exist.

4.2 Antimicrobial Activity

Evidence Base

Isoalantolactone, a major constituent of Inula racemosa (Compositae), was tested for its antimicrobial action against five bacteria, six human, and six plant pathogenic fungi. The lactone showed absolute toxicities at 500 μg/mL against 3 soil-borne phytopathogenic fungi (Gaeumannomyces graminis var. tritici, Rhizoctonia cerealis, and Phytophthora capsici), with MICs determined to be 100, 100, and 300 μg/mL, respectively.

Isoalantolactone displayed weaker antibacterial activities against Bacillus subtilis, Escherichia coli, Pseudomonas fluorescens, Sarcina lentus, and Staphylococcus aureus with MICs of 125, 425, 150, 150, and 100 μg/mL, respectively.

The natural products attributing to the antimicrobial activity of a traditional elecampane root extract were identified as alantolactone, isoalantolactone, igalan, and an unseparated mixture of dugesialactone and alloalantolactone as major compounds. The findings suggest that the geographical origin of the plant does not influence the anti-bacterial potency nor the chemical composition of traditional elecampane root.

Isoalantolactone protects against Staphylococcus aureus pneumonia. This was observed in a preclinical (animal) model.

Evidence Strength

Preliminary, in vitro and animal only. Antimicrobial activity has been demonstrated in multiple laboratory studies, and the activity against Staphylococcus aureus (including drug-resistant strains in parent plant extracts) is a significant area of interest. However, no clinical trials exist confirming antimicrobial efficacy in humans.

4.3 Anti-Inflammatory Activity

Mechanisms Studied

Through inhibiting NF-κB signaling, ISA exerts its anti-inflammatory effects, which are involved in the neuroprotection of ISA. In experimental models of sepsis and acute lung injury, isoalantolactone has demonstrated suppression of LPS-induced inflammatory mediator release, including TNF-α, IL-1β, and IL-6, in multiple cell lines and animal models.

IAL inhibited LPS-induced release of pro-inflammatory mediators in BV2 cells by activating the AKT/Nrf2/HO-1 pathway and inhibiting the NF-κB pathway.

Evidence Strength

Preliminary, preclinical only. All anti-inflammatory evidence for isoalantolactone is derived from cell culture experiments and animal models. No clinical trials in inflammatory diseases in humans have been conducted.

4.4 Neuroprotection and Neurodegenerative Disease

Alzheimer's Disease Models

ISA can suppress the generation of ROS and superoxide anion induced by amyloid β peptide (Aβ25-35) in mouse cortical neurons while elevating intracellular GSH, attenuating the cytotoxicity of Aβ25-35 to neurons. In a mouse amnesia model induced by scopolamine, ISA can decrease the damages of the cornu ammonis regions of mouse hippocampus and alleviate cognitive impairment, as revealed by Y-maze, passive avoidance, and water maze tests; in Nrf2−/− mice, however, this improvement was not observed.

Parkinson's Disease Models

Results from a preclinical study showed that IAL administration ameliorated MPTP-induced Parkinson's disease-related pathological impairment and decreased motor activity in mice. In vitro mechanistic studies showed that IAL regulated apoptosis-related proteins by activating the AKT/Nrf2 pathway, thereby suppressing the apoptosis of SN4741 cells induced by MPP+. On the other hand, IAL inhibited LPS-induced release of pro-inflammatory mediators in BV2 cells by activating the AKT/Nrf2/HO-1 pathway and inhibiting the NF-κB pathway. In addition, IAL protected SN4741 from microglial activation-mediated neurotoxicity. These results highlight the beneficial role of IAL as a novel therapy and potential PD drug due to its pharmacological profile.

Evidence Strength

Preliminary, animal and cell-based only. While results in mouse models of both Alzheimer's and Parkinson's disease are promising, all data are preclinical. No human or clinical trial data exist for neurological endpoints.

4.5 Antifungal Activity

Isoalantolactone has been reported as an efficient antimicrobial compound, active against both fungi and bacteria. Laboratory studies have documented activity against human pathogenic fungi as well as plant pathogenic fungi. The antifungal MICs reported against phytopathogenic fungi ranged from 100 to 300 μg/mL (see Section 4.2). Evidence strength is in vitro only; no clinical data exist.

4.6 Anthelmintic (Antiparasitic) Activity

Alantolactone and isoalantolactone have been reported for anthelmintic activities. This use is corroborated historically by the traditional application of elecampane root for intestinal worms across multiple cultures. Laboratory evidence for antiparasitic activity exists. No clinical trials have evaluated isoalantolactone alone as an anthelmintic agent.

4.7 Antidepressant-Like Activity

Over the past two decades, research has been made on ISA, which owns multiple pharmacological effects, including antidepressant-like activity. This property has been identified in preclinical behavioral studies. As of available published literature, no human clinical data support this application.

4.8 Adipogenesis Inhibition

Dual targeting of Nur77 and AMPKα by isoalantolactone inhibits adipogenesis in vitro and decreases body fat mass in vivo. This finding, from a study in animal models, suggests a potential role in metabolic disease research, though evidence remains entirely preclinical.

5. Body Systems and Health Areas of Association

• Oncology: Preclinical research across a wide range of cancer types—including pancreatic, lung, breast, prostate, colorectal, gastric, leukemic, glioblastoma, hepatocellular, and endometrial cancers—via apoptosis induction, cell cycle arrest, and ROS generation.
• Immune and Inflammatory System: Inhibition of NF-κB signaling; suppression of pro-inflammatory cytokines (TNF-α, IL-1β, NO); experimental models of sepsis, acute lung injury, and asthmatic inflammation.
• Nervous System: Neuroprotection against Aβ-induced toxicity; reduction of neuroinflammation in microglial models; improvement of motor and cognitive deficits in animal models of Parkinson's and Alzheimer's disease; inhibition of acetylcholinesterase.
• Respiratory System: Traditional use for bronchitis, cough, asthma, and phlegm; preclinical evidence of protection against S. aureus pneumonia; ovalbumin-induced asthmatic inflammation model.
• Gastrointestinal System: Traditional use for digestive support, appetite stimulation, and treatment of intestinal parasites; Radix Inulae used in TCM for vomiting and diarrhea.
• Microbiology / Infection: Demonstrated in vitro antimicrobial and antifungal activity against a range of pathogens; anti-staphylococcal and antifungal properties linked to traditional dermal and respiratory uses.
• Metabolic System: Preclinical evidence of inhibition of adipogenesis via Nur77/AMPKα dual targeting.

6. Pharmacokinetics

6.1 Absorption

Isoalantolactone and alantolactone are the main sesquiterpene lactones in Radix Inulae (dried root of Inula helenium L. or I. racemosa Hook. F.), which is a frequently utilized herbal medicine. They also occur in several plants and have various pharmacologic effects. However, they have been found to have poor oral bioavailability in rats. The absorption permeability of isoalantolactone and alantolactone was high at the tested concentrations (5, 20, and 80 μmol/L) in the Caco-2 cell model, and the major permeation mechanism of both lactones was passive diffusion. Since low intestinal absorption can now be ruled out as a cause, further studies are needed to explain the low oral bioavailability of the two sesquiterpene lactones.

6.2 Distribution

The present study showed poor absorption of isoalantolactone and alantolactone in vivo. The apparent Cmax, Tmax, T1/2, and total exposure (AUC0–12h) in rat plasma were 37.8 ng/mL, 120 min, 351.7 min, and 6112.3 ng·min/mL for isoalantolactone, respectively. It was shown that the highest concentration was achieved in the small intestine, and fecal clearance was the dominant elimination pathway of the lactones.

6.3 Metabolism

The metabolism of isoalantolactone in vivo and in vitro was investigated by UPLC-Q-TOF-MS. Nine metabolites in vivo including cysteine conjugates, oxidates, dehydrogenates, and hydrates were detected in rat bile after oral administration. The metabolites produced in vitro by incubation with rat liver microsomes were substantially identical to those detected in vivo. No metabolites were detected in the samples of plasma, feces, and urine or in the incubates of gastric juice, intestinal juice, and intestinal bacteria. These results reveal that the liver is the main metabolic organ for alantolactone and isoalantolactone, and the first-pass effect of the liver appears to be the reason for the low oral bioavailability of the two lactones.

A study identified 46 metabolites including 34 novel sulfur-containing products. The results demonstrated that isoalantolactone can undergo general metabolic reactions, including oxidation, hydration, hydrogenation, demethylation, cysteine conjugation, and N-acetylcysteine conjugation.

6.4 Excretion

The excretion of isoalantolactone and alantolactone in bile, urine, and feces was investigated. After a single oral dose of 90 mg/kg Radix Inulae extract, mean recovery in bile, urine, and feces was 4.18%, 0.044%, and 28.22% for isoalantolactone, respectively. Less than 32.5% of isoalantolactone was recovered from rat urine, bile, and feces after oral administration, implying that it might be excreted mainly as metabolites.

6.5 Intravenous Kinetics

After intravenous administration, isoalantolactone entered the blood immediately; the Cmax at 2 min after administration was 2.302 mg/L, and it was rapidly cleared.

7. Dosage Forms and Reported Dosages

There is no established, standardized human dosage for isolated isoalantolactone. All dosages in the primary literature refer to preclinical (cell culture or animal) experiments, or to preparations of Radix Inulae extract containing isoalantolactone as one of several active constituents.

• In vitro cell studies: PC-3 and DU145 cells were incubated with increasing doses of isoalantolactone (2.5–60 μM) for 24 h. Concentrations studied across cancer cell lines in published literature range generally from low micromolar to high micromolar ranges.
• In vivo pharmacokinetics (rat oral): A single oral dose of 90 mg/kg Radix Inulae extract was evaluated in pharmacokinetic studies.
• Traditional preparations: ISA exerts different pharmacological effects with different mechanisms of action at different doses, and may be a potential drug candidate to treat inflammatory diseases, neurodegenerative diseases, and cancer, with medicinal value.

Isoalantolactone has various pharmacological activities and medicinal values. However, further research is needed to determine its specific intracellular action sites and targets, so as to fully understand its therapeutic mechanism and provide a reference for the treatment of related diseases.

8. Safety Considerations and Interactions

8.1 Skin Sensitization and Allergic Contact Dermatitis

The α-methylene-γ-lactone moiety in isoalantolactone carries an established sensitization risk that has been the subject of formal scientific investigation. It was found that isoalantolactone, allegedly not allergenic, is in fact a sensitizer and cross-reacts with alantolactone. This was established in both human volunteer patch testing and guinea pig sensitization studies reported in the British Journal of Dermatology.

Alpha-methylene-gamma-butyrolactone itself does not elicit cross-reactions in guinea pigs sensitive either to alantolactone or to isoalantolactone, or in patients sensitive to sesquiterpene lactones. The alpha-methylene-gamma-butyrolactone group is necessary for cross-reaction, but to be active, it has first to be substituted.

A murine model produced conflicting data on relative sensitizing capacity. The haptens studied were alantolactone and isoalantolactone, two moderate allergens from Inula helenium L. Only alantolactone showed a significant response in vivo and in vitro in mice sensitized epicutaneously, without using Freund's complete adjuvant. Isoalantolactone did not show any sensitizing capacity in the murine model studied. The comparison of in vitro lymphocyte proliferation and in vivo allergenic capacity clearly demonstrates that, of the two sesquiterpene lactones, alantolactone is the better sensitizer.

This discrepancy between the guinea pig/human data and the murine model data indicates that the sensitizing potential of isoalantolactone is real but lower than that of its isomer alantolactone, and that species-dependent responses affect the experimental outcome. Individuals with known sensitivity to sesquiterpene lactones or to other members of the Asteraceae family (such as chrysanthemums, chamomile, feverfew, or arnica) may be at elevated risk.

8.2 General Toxicity Profile

Alantolactone and isoalantolactone, main bioactive compounds present in many medicinal plants such as Inula helenium, Inula japonica, Aucklandia lappa, Inula racemosa, and Radix inulae, have been found to have various pharmacological actions including anti-inflammatory, antimicrobial, and anticancer properties, with no significant toxicity in the studies reviewed. However, this assessment is based on preclinical data; comprehensive human toxicology data are absent.

Isoalantolactone has a great many biological activities such as anti-inflammatory, antioxidant, antitumor, and neuroprotection, with no obvious toxicity. This review suggests that IAL exerts different pharmacological effects with different mechanisms of action at different doses.

With the growing role of IAL in human health, it is essential to investigate its pharmacokinetic properties, efficacy, and toxicity to clarify its potential as a therapeutic and the possible health risk associated with excessive consumption of IAL from dietary sources.

8.3 Asteraceae Family Cross-Reactivity

As a constituent of plants in the Asteraceae family, isoalantolactone shares structural features with other sesquiterpene lactone allergens distributed across Compositae-family plants. Cross-sensitivity with the isoalantolactone protein conjugate was observed in animal sensitization studies. Persons with known Compositae sensitivity should exercise caution with preparations containing isoalantolactone or parent plant extracts.

8.4 Bioavailability Considerations Relevant to Safety

The liver is the main metabolic organ for isoalantolactone and alantolactone, and the first-pass effect of the liver appears to be the reason for the low oral bioavailability of the two lactones. The formation of cysteine conjugates and thiol adducts as metabolites—arising from the Michael-type reactivity of the α-methylene-γ-lactone group—represents the same chemical mechanism that drives both sensitization and biological activity. Isoalantolactone can undergo general metabolic reactions, including oxidation, hydration, hydrogenation, demethylation, cysteine conjugation, and N-acetylcysteine conjugation.

8.5 Gaps in Safety Knowledge

No systematic toxicological evaluation, carcinogenicity studies, reproductive toxicity studies, or pharmacovigilance data exist for isolated isoalantolactone in humans. The GHS hazard statement H317 ("may cause an allergic skin reaction") is associated with isoalantolactone as a reference substance. Hazard statements for the reference standard include H317, with precautionary statements including P261a, P280h, P302+P352a, P313+P333, and P501a. The clinical implications of these classifications for dietary supplement use at any dose have not been evaluated in controlled human trials.

9. Research Landscape and Future Directions

Over the past two decades, extensive research has been conducted on ISA, which possesses multiple pharmacological effects, including antimicrobial, anticancer, anti-inflammatory, neuroprotective, and antidepressant-like activity. Despite this breadth of preclinical investigation, many further and deep explorations have to be undertaken before these pharmacological activities can be translated into therapeutic options for cancers, microbial infections, inflammatory diseases, and neurodegenerative disorders.

Efforts to overcome the low oral bioavailability of isoalantolactone through structural modification are ongoing. Amino adducts improve the solubility in water and pharmacokinetics, and retain the antitumor activity. A range of synthetic conjugates have been synthesized by many researchers, including isoalantolactone-tryptamine conjugates, anthracycline antibiotic conjugates, thiophenol conjugates, selenophenol conjugates, piperazine conjugates, halopyridine conjugates, and serotonin conjugates.

The compound remains an active subject of medicinal chemistry research, with interest in its potential as a scaffold for the development of new anti-infective and anti-cancer agents. As of 2024, all pharmacological claims remain grounded in laboratory science. The transition from bench to clinical application would require formal dose-finding, safety, and efficacy trials in human subjects, none of which have yet been published.

References

• PMC11456459 — Isoalantolactone: a review on its pharmacological effects (Frontiers in Pharmacology / PubMed Central, 2024)
• Frontiers in Pharmacology — Isoalantolactone: a review on its pharmacological effects (2024)
• PMC6292114 — Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells (PubMed Central, 2018)
• PMC9133875 — Isoalantolactone Induces Cell Cycle Arrest, Apoptosis and Autophagy in Colorectal Cancer Cells (PubMed Central, 2022)
• PubMed 27600429 — Isoalantolactone induces apoptosis in human breast cancer cells via ROS-mediated mitochondrial pathway and downregulation of SIRT1 (2016)
• PMC8540929 — Induction of Apoptosis by Isoalantolactone in Human Hepatocellular Carcinoma Hep3B Cells through Activation of the ROS-Dependent JNK Signaling Pathway (PubMed Central, 2021)
• PMC9497122 — Isoalantolactone (IAL) Regulates Neuro-Inflammation and Neuronal Apoptosis to Curb Pathology of Parkinson's Disease (PubMed Central, 2022)
• Cells 2022, 11, 2927 — Isoalantolactone (IAL) Regulates Neuro-Inflammation and Neuronal Apoptosis to Curb Pathology of Parkinson's Disease
• PMC8874828 — From Monographs to Chromatograms: The Antimicrobial Potential of Inula helenium L. (Elecampane) Naturalised in Ireland (PubMed Central, 2022)
• Molecules 2022, 27(4), 1406 — From Monographs to Chromatograms: The Antimicrobial Potential of Inula helenium L. (MDPI)
• Chinese Science Bulletin, 2001 — Antimicrobial activities of isoalantolactone, a major sesquiterpene lactone of Inula racemosa (Springer)
• PMC4355875 — Microwave-assisted Extraction of Alantolactone and Isoalantolactone from Inula helenium (PubMed Central, 2015)
• South African Journal of Botany, 2016 — Isoalantolactone from Artemisia afra and in vitro mechanism of induced cell death in HeLa cells (ScienceDirect)
• The Scientific World Journal, 2013 — Targeting Apoptosis Pathways in Cancer with Alantolactone and Isoalantolactone (Hindawi)
• PMC6272429 — Pharmacokinetics, Tissue Distribution and Excretion of Isoalantolactone and Alantolactone in Rats after Oral Administration of Radix Inulae Extract (PubMed Central, 2018)
• Journal of Chemistry, 2018 — Metabolism Analysis of Alantolactone and Isoalantolactone in Rats by Oral Administration (Hindawi)
• Food Chemistry, 2017 — Study on the metabolites of isoalantolactone in vivo and in vitro by UPLC-Triple TOF-MS (ScienceDirect)
• European Journal of Drug Metabolism and Pharmacokinetics, 2019 — Intestinal Absorption of Isoalantolactone and Alantolactone Using Caco-2 Cells (Springer)
• Journal of Pharmacy and Pharmacology, 2023 — Research progress on pharmacological effects of isoalantolactone (Oxford Academic)
• PubMed 698105 — Allergic contact dermatitis due to sesquiterpene lactones. A comparative study of human and animal sensitivity to alpha-methylene-gamma-butyrolactone and derivatives (British Journal of Dermatology, 1978)
• PubMed 1444579 — A murine in vitro model of allergic contact dermatitis to sesquiterpene alpha-methylene-gamma-butyrolactones (1992)
• Drugs.com Natural Products — Elecampane: Uses, Benefits & Dosage (evidence-referenced monograph)